Abstract
Each individual has an inherent variable risk of bleeding linked to genetic or acquired abnormal platelet number or platelet dysfunction. In contrast, it is less obvious that the variability of platelet phenotypes (number, mean platelet volume, function) may contribute to the variable individual risk of thrombosis. Interindividual variability of platelet indices or function may be either due to acquired factors, such as age, sex, metabolic variables, smoke, dietary habits, and ongoing inflammation, or due to genetic factors. Acquired variables explain a small portion of the heterogeneity of platelet parameters. Genetic factors, instead, appear to play a major role, although a consistent portion of such a genetic variance has not yet been attributed to any specific genetic factor, possibly due to the high number of DNA loci potentially involved and to the limited effect size of each individual SNP. A portion of variance remains thus unexplained, also due to variability of test performance. A major contradiction in present platelet knowledge is, indeed, the difficulty to reconcile the universally accepted importance of platelet indices or function and the lack of reliable platelet parameters in cardiovascular risk prediction models. Trials on antiplatelet drugs were generally designed to select a homogeneous sample, whose results could be applied to an “average subject,” tending to exclude the deviation/extreme values. As the current indications for antiplatelet treatment in primary or secondary prevention of ischemic vascular disease still derive from the results of such clinical trials where platelet function and its variability was not investigated, we cannot at present rely upon any current platelet test to either initiate, or monitor, or modify or stop treatment with any antiplatelet drug. Evidence is, however, increasing that traditional platelet aggregometry and other more recently developed platelet function assays could be useful to optimize antiplatelet therapy and to predict major adverse cardiac events.The observation of interindividual differences in platelet response to antiplatelet drugs has enlarged the spectrum and the possible clinical relevance of the variability of platelet indices or function. The development of “personalized medicine” will benefit from the concepts discussed in this chapter.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Albers AR, Varghese S, Vitseva O et al (2004) The anti-inflammatory effects of purple grape juice consumption in subjects with stable coronary artery disease. Arterioscler Thromb Vasc Biol 24:e179–e180
Angiolillo DJ, Fernández-Ortiz A, Bernardo E et al (2004) High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability. Eur Heart J 25:1903–1910
Antithrombotic Trialists’ (ATT) Collaboration, Baigent C, Blackwell L, Collins R et al (2009) Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 373:1849–1860
Antithrombotic Trialists’ Collaboration (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324:71–86
Bain BJ (1996) Ethnic and sex differences in the total and differential white cell count and platelet count. J Clin Pathol 49:664–666
Barbalic M, Dupuis J, Dehghan A et al (2010) Large-scale genomic studies reveal central role of ABO in sP-selectin and sICAM-1 levels. Hum Mol Genet 19:1863–1872
Bath PM, Butterworth RJ (1996) Platelet size: measurement, physiology and vascular disease. Blood Coagul Fibrinolysis 7:157–161
Bath P, Algert C, Chapman N et al (2004) Association of mean platelet volume with risk of stroke among 3134 individuals with history of cerebrovascular disease. Stroke 35:622–626
Becker DM, Segal J, Vaidya D et al (2006) Sex differences in platelet reactivity and response to low-dose aspirin therapy. J Am Coll Cardiol 295:1420–1427
Belch J, MacCuish A, Campbell I, Prevention of Progression of Arterial Disease and Diabetes Study Group, Diabetes Registry Group, Royal College of Physicians Edinburgh et al (2008) The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. Br Med J 337:a1840
Berger JS, Eraso LH, Xie D et al (2010) Mean platelet volume and prevalence of peripheral artery disease, the National Health and Nutrition Examination Survey, 1999–2004. Atherosclerosis 213:586–591
Bernlochner I, Byrne RA, Kastrati A et al (2011) The future of platelet function testing to guide therapy in clopidogrel low and enhanced responders. Expert Rev Cardiovasc Ther 9:999–1014
Bertelé V, Cerletti C, Schieppati A et al (1981) Inhibition of thromboxane synthetase does not necessarily prevent platelet aggregation. Lancet 1:1057–1058
Bertelé V, Falanga A, Tomasiak M et al (1984) Pharmacologic inhibition of thromboxane synthetase and platelet aggregation: modulatory role of cyclooxygenase products. Blood 63:1460–1466
Biino G, Balduini CL, Casula L et al (2011) Analysis of 12, 517 inhabitants of Sardinian geographic isolate reveals that propensity to develop mild thrombocytopenia during ageing and to present mild, transient thrombocytosis in youth are new genetic traits. Haematologica 96:96–101
Bliden KP, Dichiara J, Lawal L et al (2008) The association of cigarette smoking with enhanced platelet inhibition by clopidogrel. J Am Coll Cardiol 52:531–533
Bonello L, Tantry US, Marcucci R, Working Group on High On-Treatment Platelet Reactivity et al (2010) Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 56:919–933
Born GV (1962) Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 194:927–929
Bouman HJ, Schomig E, van Werkum JW et al (2010) Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat Med 17:110–116
Braekkan SK, Mathiesen EB, Njølstad I et al (2010) Mean platelet volume is a risk factor for venous thromboembolism: the Tromsø Study, Tromsø, Norway. J Thromb Haemost 8:157–162
Bray PF, Mathias RA, Faraday N et al (2007a) Heritability of platelet function in families with premature coronary artery disease. J Thromb Haemost 5:1617–1623
Bray PF, Howard TD, Vittinghoff E et al (2007b) Effect of genetic variations in platelet glycoproteins Ibalpha and VI on the risk for coronary heart disease events in postmenopausal women taking hormone therapy. Blood 109:1862–1869
Campo G, Miccoli M, Tebaldi M et al (2011) Genetic determinants of on-clopidogrel high platelet reactivity. Platelets 22:399–407
Catella-Lawson F, Reilly MP, Kapoor SC et al (2001) Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 345:1809–1817
Cattaneo M (2003) Inherited platelet-based bleeding disorders. J Thromb Haemost 1:1628–1636
Cattaneo M (2004) Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance. Arterioscler Thromb Vasc Biol 24:1980–1987
Cattaneo M, Cerletti C, Harrison P et al (2010) Final report of the Working Party on LTA Standardization. In: 56th annual SSC meeting of the International Society on thrombosis and haemostasis, Cairo, Egypt
Cauwenberghs S, van Pampus E, Curvers J et al (2007) Hemostatic and signaling functions of transfused platelets. Transfus Med Rev 21:287–294
Centritto F, Iacoviello L, di Giuseppe R et al (2009) Dietary patterns, cardiovascular risk factors and C reactive protein in a healthy Italian population. Nutr Metab Cardiovasc Dis 19:697–706
Cerletti C, Carriero MR, de Gaetano G (1986) Platelet-aggregation response to single or paired aggregating stimuli after low-dose aspirin. N Engl J Med 314:316–318
Cerletti C, Tamburrelli C, Izzi B et al (2011) Platelet-leukocyte interactions in thrombosis. Thromb Res. 129:263–266
Chu SG, Becker RC, Berger PB et al (2010) Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta-analysis. J Thromb Haemost 8:148–156
Clappers N, van Oijen MG, Sundaresan S et al (2008) The C50T polymorphism of the cyclooxygenase-1 gene and the risk of thrombotic events during low-dose therapy with acetyl salicylic acid. Thromb Haemost 100:70–75
Coban E, Afacan B (2008) The effect of rosuvastatin treatment on the mean platelet volume in patients with uncontrolled primary dyslipidemia with hypolipidemic diet treatment. Platelets 19:111–114
Cortellaro M, Boschetti C, Cofrancesco E et al (1992) The PLAT Study: hemostatic function in relation to atherothrombotic ischemic events in vascular disease patients. Principal results. PLAT Study Group. Progetto Lombardo Atero-Trombosi (PLAT) Study Group. Arterioscler Thromb 12:1063–1070
Crescente M, Di Castelnuovo A, Iacoviello L et al (2008a) Response variability to aspirin as assessed by platelet function analyzer (PFA-100): a systematic review. Thromb Haemost 99:14–26
Crescente M, Di Castelnuovo A, Iacoviello L et al (2008b) PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: a metaanalysis of 19 studies comprising 3003 patients. Thromb Haemost 99:1129–1131
Crescente M, Jessen G, Momi S et al (2009) Interactions of gallic acid, resveratrol, quercetin and aspirin at the platelet cyclooxygenase-1 level. Functional and modelling studies. Thromb Haemost 102:336–346
Crescente M, Mezzasoma AM, Del Pinto M et al (2011) Incomplete inhibition of platelet function as assessed by the platelet function analyzer (PFA-100) identifies a subset of cardiovascular patients with high residual platelet response while on aspirin. Platelets 22:179–187
Curvers J, van Pampus ECM, Feijge MAH et al (2004) Decreased responsiveness and development of activation markers of platelets stored in plasma. Transfusion 44:49–58
de Gaetano G (2001) Historical overview of the role of platelets in hemostasis and thrombosis. Haematologica 86:349–356
de Gaetano G, Cerletti C (2003) Aspirin resistance: a revival of platelet aggregation tests? J Thromb Haemost 1:2048–2050
de Gaetano G, Cerletti C (2007) Platelet function, antiplatelet therapy and clinical outcomes: to test or not to test? J Thromb Haemost 5:1835–1838
de Gaetano G, Vermylen J, Donati MB et al (1974) Indomethacin and platelet aggregation in chronic glomerulonephritis: existence of non-responders. Br Med J 2:301–303
de Gaetano G, Cerletti C, Dejana E et al (1985) Pharmacology of platelet inhibition in humans. Implications of the salicylate-aspirin interaction. Circulation 72:1185–1193
de Gaetano G, Cerletti C, Iacoviello L (2002) Pharmacogenetics as a new antiplatelet strategy. In: Gresele P, Page CP, Fuster V, Vermylen J (eds) Platelets in thrombotic and non thrombotic disorders. Cambridge University Press, Cambridge, pp 964–977
de Gaetano G, Cerletti C, Iacoviello L et al (2003) The epidemiological night where all patients are black: will pharmacogenetics shed some light? Thromb Res 112:273–274
de Gaetano G, Crescente M, Cerletti C (2008) Current concepts about inhibition of platelet aggregation. Platelets 19:565–570
De Luca G, Venegoni L, Iorio S et al (2010) Platelet distribution width and the extent of coronary artery disease: results from a large prospective study. Platelets 21:508–514
Della Corte A, Tamburrelli C, Crescente M et al (2012) Platelet proteome in healthy volunteers who smoke. Platelets 23:91–105
Den Dekker E, van Abel M, van der Vuurst H et al (2003) Cell-to-cell variability in the differentiation program of human megakaryocytes. Biochim Biophys Acta 1643:85–94
Desai NR, Mega JL, Jiang S et al (2009) Interaction between cigarette smoking and clinical benefit of clopidogrel. J Am Coll Cardiol 53:1273–1278
Di Minno G, Silver MJ, Cerbone AM et al (1986) Trial of repeated low-dose aspirin in diabetic angiopathy. Blood 68:886–891
Eikelboom JW, Hirsh J, Weitz JI et al (2002) Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 105:1650–1655
Faraday N, Becker DM, Becker LC (2007a) Pharmacogenomics of platelet responsiveness to aspirin. Pharmacogenomics 8:1413–1425
Faraday N, Yanek LR, Mathias R et al (2007b) Heritability of platelet responsiveness to aspirin in activation pathways directly and indirectly related to cyclooxygenase-1. Circulation 115:2490–2496
Femia EA, Pugliano M, Podda G et al (2012) Comparison of different procedures to prepare platelet-rich plasma for studies of platelet aggregation by light transmission aggregometry. Platelets 23:7–10
Ferreira MA, Hottenga JJ, Warrington NM et al (2009) Sequence variants in three loci influence monocyte counts and erythrocyte volume. Am J Hum Genet 85:745–749
Fitzgerald R, Pirmohamed M (2011) Aspirin resistance: effect of clinical, biochemical and genetic factors. Pharmacol Ther 130:213–225
Fontana P, Dupont A, Gandrille S et al (2003) Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects. Circulation 108:989–995
Freedman JE (2007) Heritability, platelet function, and aspirin: a link established but cause unknown. Circulation 115:2468–2470
Frelinger AL, Furman MI, Linden MD et al (2006) Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase- 2-independent pathway. Circulation 113:2888–2896
Garg SK, Amorosi EL, Karpatkin S (1971) Use of the megathrombocyte as an index of megakaryocyte number. N Engl J Med 284:11–17
Garner C, Tatu T, Reittie JE et al (2000) Genetic influences on F cells and other hematologic variables: a twin heritability study. Blood 95:342–346
Gaxiola B, Friedl W, Propping P (1984) Epinephrine-induced platelet aggregation. A twin study. Clin Genet 26:543–548
Gianfagna F, Cugino D, Santimone I et al (2012a) From candidate genes to genome-wide association studies in cardiovascular disease. Thromb Res 129(3):320–324, PMID: 22154244
Gianfagna F, Tamburrelli C, Vonhout B, Moli-family Study Investigators et al (2012b) Heritability, genetic correlation and linkage to 9p21 region of mixed platelet-leukocytes conjugates in families with and without early myocardial infarction. Nutr Metab Cardiovasc Dis. May 25. [Epub ahead of print]
Giles H, Smith RE, Martin JF (1994) Platelet glycoprotein IIb–IIIa and size are increased in acute myocardial infarction. Eur J Clin Invest 24:69–72
Goodall AH, Burns P, Salles I et al (2010) Transcription profiling in human platelets reveals LRRFIP1 as a novel protein regulating platelet function. Blood 116:4646–4656
Goodman T, Ferro A, Sharma P (2008) Pharmacogenetics of aspirin resistance: a comprehensive systematic review. Br J Clin Pharmacol 66:222–232
Gresele P, Blockmans D, Deckmyn H et al (1988) Adenylate cyclase activation determines the effect of thromboxane synthase inhibitors on platelet aggregation in vitro. Comparison of platelets from responders and nonresponders. J Pharmacol Exp Ther 246:301–307
Gresele P, Deckmyn H, Nenci GG et al (1991) Thromboxane synthase inhibitors, thromboxane receptor antagonists and dual blockers in thrombotic disorders. Trends Pharmacol Sci 12:158–163
Guerrero JA, Rivera J, Quiroga T et al (2011) Novel loci involved in platelet function and platelet count identified by a genome-wide study performed in children. Haematologica 96:1335–1343
Gurbel PA, Bliden KP, Hiatt BL et al (2003) Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 107:2908–2913
Guthikonda S, Alviar CL, Vaduganathan M et al (2008) Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease. J Am Coll Cardiol 52:743–749
Hardy AR, Conley PB, Luo J et al (2005) P2Y1 and P2Y12 receptors for ADP desensitize by distinct kinase-dependent mechanisms. Blood 105:3552–3560
Harismendy O, Notani D, Song X et al (2011) 9p21 DNA variants associated with coronary artery disease impair interferon-γ signalling response. Nature 470:264–268
Hayward CP, Eikelboom J (2007) Platelet function testing: quality assurance. Semin Thromb Hemost 33:273–282
Hendra TJ, Oswald GA, Yudkin JS (1988) Increased mean platelet volume after acute myocardial infarction relates to diabetes and to cardiac failure. Diabetes Res Clin Pract 5:63–69
Heptinstall S, Fox SC (1983) Human blood platelet behaviour after inhibition of thromboxane synthetase. Br J Clin Pharmacol 15(Suppl 1):31S–37S
Hoffmeister KM, Felbinger TW, Falet H et al (2003) The clearance mechanism of chilled blood platelets. Cell 112:87–97
Huczek Z, Kochman J, Filipiak KJ et al (2005) Mean platelet volume on admission predicts impaired reperfusion and longterm mortality in acute myocardial infarction treated with primary percutaneous coronary intervention. J Am Coll Cardiol 46:284–290
Iacoviello L, Bonanni A, Costanzo S et al (2007) The Moli-Sani Project, a randomized, prospective cohort study in the Molise region in Italy; design, rationale and objectives. Ital J Public Health 4:110–118
Iacoviello L, Vohnout B, Gianfagna F et al (2009) Genetic regulation of inflammation-mediated haemostasis activation: a family-based approach. J Thromb Haemost 7(Suppl 2):S710
Jakubowski JA, Adler B, Thompson CB et al (1985) Influence of platelet volume on the ability of prostacyclin to inhibit platelet aggregation and the release reaction. J Lab Clin Med 105:271–276
Johnson AD (2011) The genetics of common variation affecting platelet development, function and pharmaceutical targeting. J Thromb Haemost 9(Suppl 1):246–257
Johnson AD, Yanek LR, Chen MH et al (2010) Genome-wide meta-analyses identifies seven loci associated with platelet aggregation in response to agonists. Nat Genet 42:608–613
Jones CI, Bray S, Garner SF, Bloodomics Consortium et al (2009) A functional genomics approach reveals novel quantitative trait loci associated with platelet signaling pathways. Blood 114:1405–1416
Kamath S, Blann AD, Lip GY (2001) Platelet activation: assessment and quantification. Eur Heart J 22:1561–1571
Karpatkin S, Khan Q, Freedman M (1978) Heterogeneity of platelet function. Correlation with platelet volume. Am J Med 64:542–546
Kathiresan S, Voight BF, Purcell S et al (2009) Genomewide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat Genet 41:334–341
Kawasaki T, Ozeki Y, Igawa T et al (2000) Increased platelet sensitivity to collagen in individuals resistant to low-dose aspirin. Stroke 31:591–595
Kazui M, Nishiya Y, Ishizuka T et al (2010) Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos 38:92–99
Knight CJ, Panesar M, Wright C et al (1997) Altered platelet function detected by flow cytometry. Effects of coronary artery disease and age. Arterioscler Thromb Vasc Biol 17:2044–2053
Kondkar AA, Bray MS, Leal SM et al (2010) VAMP8/endobrevin is overexpressed in hyperreactive human platelets: suggested role for platelet microRNA. J Thromb Haemost 8:369–378
Krasopoulos G, Brister SJ, Beattie WS et al (2008) Aspirin “resistance” and risk of cardiovascular morbidity: systematic review and meta-analysis. Br Med J 336:195–198
Kunicki TJ (2002) The influence of platelet collagen receptor polymorphisms in hemostasis and thrombotic disease. Arterioscler Thromb Vasc Biol 22:14–20
Kunicki TJ, Nugent DJ (2010) The genetics of normal platelet reactivity. Blood 116:2627–2634
Lepäntalo A, Mikkelsson J, Reséndiz JC et al (2006) Polymorphisms of COX-1 and GPVI associate with the antiplatelet effect of aspirin in coronary artery disease patients. Thromb Haemost 95:253–259
Lev EI, Solodky A, Harel N et al (2010) Treatment of aspirin-resistant patients with omega-3 fatty acids versus aspirin dose escalation. J Am Coll Cardiol 55:114–121
Lindemann JP, Kang KW, Christian JC (1977) Genetic variance of erythrocyte parameters in adult male twins. Clin Genet 12:73–76
Livio M, Del Maschio A, Cerletti C et al (1982) Indomethacin prevents the long-lasting inhibitory effect of aspirin on human platelet cyclo-oxygenase activity. Prostaglandins 23:787–796
Macchi L, Christiaens L, Brabant S et al (2002) Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate. Thromb Res 107:45–49
Marcucci R, Gori AM, Paniccia R et al (2007) Residual platelet reactivity is associated with clinical and laboratory characteristics in patients with ischemic heart disease undergoing PCI on dual antiplatelet therapy. Atherosclerosis 195:e217–e223
Martin JF, Bath PM, Burr ML (1991) Influence of platelet size on outcome after myocardial infarction. Lancet 338:1409–1411
Mathias RA, Kim Y, Sung H et al (2010) A combined genome-wide linkage and association approach to find susceptibility loci for platelet function phenotypes in European American and African American families with coronary artery disease. BMC Med Genomics 3:22
May JA, Heptinstall S, Cole AT et al (1997) Platelet responses to several agonists and combinations of agonists in whole blood: a placebo controlled comparison of the effects of a once daily dose of plain aspirin 300 mg, plain aspirin 75 mg and enteric coated aspirin 300 mg, in man. Thromb Res 88:183–192
Michelson AD, Frelinger AL 3rd, Furman MI (2006) Current options in platelet function testing. Am J Cardiol 98:4N–10N
Munnix IC, Cosemans JM, Auger JM et al (2009) Platelet response heterogeneity in thrombus formation. Thromb Haemost 102:1149–1156
Musunuru K, Post WS, Herzog W et al (2010) Association of single nucleotide polymorphisms on chromosome 9p21.3 with platelet reactivity: a potential mechanism for increased vascular disease. Circ Cardiovasc Genet 3:445–453
Nagalla S, Shaw C, Kong X et al (2011) Platelet microRNA-mRNA coexpression profiles correlate with platelet reactivity. Blood 117:5189–5197
Nagata Y, Yoshikawa J, Hashimoto A et al (2003) Proplatelet formation of megakaryocytes is triggered by autocrine-synthesized estradiol. Genes Dev 17:2864–2869
Neubauer H, Kaiser AF, Endres HG et al (2011) Tailored antiplatelet therapy can overcome clopidogrel and aspirin resistance–the BOchum CLopidogrel and Aspirin Plan (BOCLA-Plan) to improve antiplatelet therapy. BMC Med 9:3
Nurden A, Nurden P (2011) Advances in our understanding of the molecular basis of disorders of platelet function. J Thromb Haemost 9(Suppl 1):76–91
O’Brien JR (1968) Effects of salicylates on human platelets. Lancet 1:779–783
O’Donnell CJ, Larson MG, Feng D, Framingham Heart Study et al (2001) Genetic and environmental contributions to platelet aggregation. The Framingham Heart Study. Circulation 103:3051–3056
Ohmori T, Yatomi Y, Nonaka T et al (2006) Aspirin resistance detected with aggregometry cannot be explained by cyclooxygenase activity: involvement of other signaling pathway(s) in cardiovascular events of aspirin-treated patients. J Thromb Haemost 4:1271–1278
Patrignani P, Filabozzi P, Patrono C (1982) Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 69:1366–1372
Patrono C (2003) Aspirin resistance: definition, mechanisms and clinical read-outs. J Thromb Haemost 1:1710–1713
Peace AJ, Tedesco AF, Foley DP et al (2008) Dual antiplatelet therapy unmasks distinct platelet reactivity in patients with coronary artery disease. J Thromb Haemost 6:2027–2034
Quick AJ (1966) Salicylates and bleeding: the aspirin tolerance test. Am J Med Sci 252:265–269
Quinn MJ, Topol EJ (2001) Common variations in platelet glycoproteins: pharmacogenomic implications. Pharmacogenomics 2:341–352
Rao GH, Reddy RK, White JG (1981) Low dose aspirin, platelet function and prostaglandin synthesis: influence of epinephrine and alpha adrenergic blockade. Prostaglandins Med 6:485–494
Reiner AP, Carlson CS, Thyagarajan B et al (2008) Soluble P-selectin, SELP polymorphisms, and atherosclerotic risk in European-American and African-African young adults: the Coronary Artery Risk Development in Young Adults (CARDIA) Study. Arterioscler Thromb Vasc Biol 28:1549–1555
Ren Q, Barber HK, Crawford GL et al (2007) Endobrevin/VAMP-8 is the primary v-SNARE for the platelet release reaction. Mol Biol Cell 18:24–33
Reny JL, De Moerloose P, Dauzat M et al (2008) Use of the PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: a systematic review and meta-analysis. J Thromb Haemost 6:444–450
Ridker PM, Cook NR, Lee IM et al (2005) A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 352:1293–1304
Sacco M, Pellegrini F, Roncaglioni MC, PPP Collaborative Group et al (2003) Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. Diabetes Care 26:3264–3272
Santilli F, Rocca B, De Cristofaro R, Lattanzio S et al (2009) Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin “resistance”. J Am Coll Cardiol 53:667–677
Santimone I, Di Castelnuovo A, De Curtis A, MOLI-SANI Project Investigators et al (2011) White blood cell count, sex and age are major determinants of heterogeneity of platelet indices in an adult general population: results from the MOLI-SANI project. Haematologica 96:1180–1188
Segal JB, Moliterno AR (2006) Platelet counts differ by sex, ethnicity, and age in the United States. Ann Epidemiol 16:123–130
Seyfert UT, Haubelt H, Vogt A et al (2007) Variables influencing Multiplate whole blood impedance platelet aggregometry and turbidimetric platelet aggregation in healthy individuals. Platelets 18:199–206
Shuldiner AR, O’Connell JR, Bliden KP et al (2009) Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. J Am Coll Cardiol 302:849–857
Sikorski K, Czerwoniec A, Bujnicki JM et al (2011) STAT1 as a novel therapeutical target in pro-atherogenic signal integration of IFNγ, TLR4 and IL-6 in vascular disease. Cytokine Growth Factor Rev 22:211–219
Smith JB, Willis AL (1971) Aspirin selectively inhibits prostaglandin production in human platelets. Nat New Biol 231:235–237
Smith NM, Pathansali R, Bath PM (2002) Altered megakaryocyte-platelet-haemostatic axis in patients with acute stroke. Platelets 13:113–120
Snoep JD, Hovens MM, Eikenboom JC et al (2007) Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch Intern Med 167:1593–1599
Sofi F, Marcucci R, Gori AM et al (2008) Residual platelet reactivity on aspirin therapy and recurrent cardiovascular events – a meta-analysis. Int J Cardiol 128:166–171
Sofi F, Marcucci R, Gori AM et al (2010) Clopidogrel non-responsiveness and risk of cardiovascular morbidity. An updated meta-analysis. Thromb Haemost 103:841–848
Soranzo N, Spector TD, Mangino M et al (2009a) A genome-wide meta-analysis identifies 22 loci associated with eight hematological parameters in the HaemGen consortium. Nat Genet 41:1182–1190
Soranzo N, Rendon A, Gieger C et al (2009b) A novel variant on chromosome 7q22.3 associated with mean platelet volume, counts, and function. Blood 113:3831–3837
Stef G, Csiszar A, Lerea K et al (2006) Resveratrol inhibits aggregation of platelets from high-risk cardiac patients with aspirin resistance. J Cardiovasc Pharmacol 48:1–5
Takahashi S, Ushida M, Komine R et al (2007) Increased basal platelet activity, plasma adiponectin levels, and diabetes mellitus are associated with poor platelet responsiveness to in vitro effect of aspirin. Thromb Res 119:517–524
Taubert D, von Beckerath N, Grimberg G et al (2006) Impact of P-glycoprotein on clopidogrel absorption. Clin Pharmacol Ther 80:486–501
Thaulow E, Erikssen J, Sandvik L et al (1991) Blood platelet count and function are related to total and cardiovascular death in apparently healthy men. Circulation 84:613–617
Thompson CB, Jakubowski JA (1988) The pathophysiology and clinical relevance of platelet heterogeneity. Blood 72:1–8
Totani L, Evangelista V (2010) Platelet-leukocyte interactions in cardiovascular disease and beyond. Arterioscler Thromb Vasc Biol 30:2357–2361
Traglia M, Sala C, Masciullo C et al (2009) Heritability and demographic analyses in the large isolated population of Val Borbera suggest advantages in mapping complex traits genes. PLoS One 4:e7554
Turner-Stokes L, Jones D, Patterson KG et al (1991) Measurement of haematological indices of chronic rheumatic disease with two newer generation automated systems, the H1 and H6000 (Technicon). Ann Rheum Dis 50:583–587
van de Loo JC (1989) Predictive value of factors of the hemostatic system in screening procedures for coronary artery disease. Ric Clin Lab 19:333–338
van der Bom JG, Heckbert SR, Lumley T et al (2009) Platelet count and the risk for thrombosis and death in the elderly. J Thromb Haemost 7:399–405
van der Loo B, Martin JF (1999) A role for changes in platelet production in the cause of acute coronary syndromes. Arterioscler Thromb Vasc Biol 19:672–679
Vermylen J, de Gaetano G, Verstraete M (eds) (1971) Round-the-table conference on normal and modified platelet aggregation, Leuven-Brussels, 25–26 Sept 1970. Acta Medica Scandinavica Suppl 525
Vohnout B, Gianfagna F, Lorenzet R, Moli-family Study Investigators et al (2011) Genetic regulation of inflammation-mediated activation of haemostasis: family based approaches in population studies. Nutr Metab Cardiovasc Dis 21:857–861
Wallentin L, James S, Storey RF et al (2010) Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet 376:1320–1328
Weiss HJ, Aledort LM, Kochwa S (1968) The effect of salicylates on the hemostatic properties of platelets in man. J Clin Invest 47:2169–2180
White JG (2007) Platelet pathology in carriers of the X-linked GATA-1 macrothrombocytopenia. Platelets 18:620–627
Whitfield JB, Martin NG (1985) Genetic and environmental Influences on the size and number of cells in the blood. Genet Epidemiol 2:133–144
Yee DL, Sun CW, Bergeron AL et al (2005) Aggregometry detects platelet hyperreactivity in healthy individuals. Blood 106:2723–2729
Acknowledgements
This review was prepared in the frame of a research project funded by the Italian Ministry of Research (MIUR, decreto N. 1588).
Thanks are due to Maria Benedetta Donati for her constructive criticism.
The authors declare no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
de Gaetano, G., Santimone, I., Gianfagna, F., Iacoviello, L., Cerletti, C. (2012). Variability of Platelet Indices and Function: Acquired and Genetic Factors. In: Gresele, P., Born, G., Patrono, C., Page, C. (eds) Antiplatelet Agents. Handbook of Experimental Pharmacology, vol 210. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-29423-5_16
Download citation
DOI: https://doi.org/10.1007/978-3-642-29423-5_16
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-29422-8
Online ISBN: 978-3-642-29423-5
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)